Destiny Pharma plc
(“Destiny Pharma” or the “Company”)
Destiny Pharma’s lead asset, XF-73, well positioned to address the global threat of anti-microbial resistance highlighted in new UK government report
Brighton, United Kingdom – 24 October 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), welcomes a recent report from the UK government’s health and social care committee focusing on the global threat of AMR and the urgent need for new treatments to tackle infections.
Destiny Pharma’s novel drug candidate, XF-73, is currently in Phase II clinical development and is designed to deliver a profile that specifically targets the prevention of post-surgical infections, such as methicillin-resistant Staphylococcus aureus (MRSA). Unlike most antibiotics, XF-73 has not been seen to generate bacterial resistance in industry-standard microbiology tests to date and therefore also has significant potential to address the global threat of AMR alongside its fast, safe and effective anti-infective action.
Neil Clark, Chief Executive Officer of Destiny Pharma, commented:
“If we are successful in the development of our lead asset, XF-73 will be a novel drug to prevent post-surgical infections with the profile required to meet the AMR challenges highlighted by the UK government this week. We remain well-funded through to H2 2020 as we seeks to address this global issue, estimated in the US alone to be a $1 billion sales opportunity.”
The full report from the UK government’s health and social care committee can be found here.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
+44 (0)1273 704 440
Simon Conway / Victoria Foster Mitchell
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as “superbugs”. Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com